MCM
TBPH icon

MAI Capital Management’s Theravance Biopharma TBPH Stock Holding History

MAI Capital Management’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1,002
Closed -$16.3K – 4438
2026
Q1 		$16.3K Buy
1,002
+2
+0.2% +$35 ﹤0.01% 2904
2025
Q4 		$18.7K Hold
1,000
– – ﹤0.01% 2547
2025
Q3 		$14.6K Hold
1,000
– – ﹤0.01% 2563
2025
Q2 		$11K Hold
1,000
– – ﹤0.01% 2677
2025
Q1 		$8.93K Sell
1,000
-1,000
-50% -$9.31K ﹤0.01% 2526
2024
Q4 		$18.8K Buy
+2,000
New +$18.2K ﹤0.01% 2249

Other funds holding TBPH

MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return
ICM
Irenic Capital Management New York $2.08B AUM 19.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

MAI Capital Management's TBPH Position: Q2 2026 in Review

MAI Capital Management sold out of Theravance Biopharma (TBPH) in Q2 2026, closing a stake of 1,002 shares — an estimated $16.3K sold.

MAI Capital Management first reported a position in TBPH in Q4 2024 and held it in 6 quarters. The position peaked at $18.8K in Q4 2024. 180 funds tracked by Wall St. Rank hold TBPH as of Q2 2026.

  • MAI Capital Management reported no remaining Theravance Biopharma position as of Q2 2026 after selling out during the quarter.
  • MAI Capital Management sold 1,002 Theravance Biopharma shares in Q2 2026, an estimated $16.3K.
  • MAI Capital Management first reported a position in Theravance Biopharma in Q4 2024 and held it in 6 quarters.
  • MAI Capital Management's Theravance Biopharma position peaked at $18.8K in Q4 2024.
  • 180 funds tracked by Wall St. Rank held Theravance Biopharma as of Q2 2026.

Based on MAI Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.